DJIA 17,265.99 109.14 0.64%
NASDAQ 4,593.43 31.24 0.68%
S&P 500 2,011.36 9.79 0.49%
market minute promo

Dendreon Corp (NASDAQ: DNDN)

1.42 -0.06 (-4.05%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

DNDN $1.42 -4.05%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.48
Previous Close $1.48
Daily Range $1.41 - $1.50
52-Week Range $1.24 - $3.52
Market Cap $227.6M
P/E Ratio -1.09
Dividend (Yield) $0.00 (0.0%)
Volume 1,363,045
Average Daily Volume 2,702,091
Current FY EPS -$0.73

Sector

Healthcare

Industry

Drugs

Dendreon Corp (DNDN) Description

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website: http://www.dendreon.com/

News & Commentary

Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014

Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape

Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious

Medivation Eyes Blockbuster As Cancer Drug Gets An OK

Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca

Medivation and Astellas get expanded FDA approval for Xtandi with a label that looks better than Johnson & Johnson's Zytiga.

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

MannKind Corp. And The Folly Of Cult Biotech Stocks

Aug. 18 Premarket Briefing: 10 Things You Should Know

Ebola Vaccine and Inhaled Insulin Incoming

Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.

A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

See More DNDN News...

DNDN's Top Competitors

DNDN $1.42 (-4.05%)
Current stock: DNDN
GILD $105.93 (2.01%)
Current stock: GILD
CELG $93.27 (1.09%)
Current stock: CELG
BIIB $329.99 (0.74%)
Current stock: BIIB